HUMACYTE INC (HUMA)

These stocks are gapping in today's session

Today's session on Monday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.

Humacyte Acellular Tissue Engineered Vessel (ATEV™) Receives FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation for Patients with Advanced Peripheral Artery Disease (PAD)

– Third RMAT designation by FDA for ATEV – – RMAT will expedite development of ATEV in PAD – DURHAM, N.C., July 01, 2024 (GLOBE NEWSWIRE) --...

Humacyte Presents Positive Preclinical Data For Its BioVascular Pancreas (BVP™) Program

– BioVascular Pancreas (BVP) product candidate is under development as a potential treatment for type 1 diabetes – – Humacyte’s stem cell-derived...

Centers for Medicare & Medicaid Services (CMS) Issues ICD-10-PCS Codes for Humacyte’s Human Acellular Vessel™ (HAV™)

– Four unique ICD-10-PCS codes, effective October 1, 2024, for replacement of arteries in the upper and lower extremities using Humacyte’s HAV – – BLA...

Humacyte (HUMA) stock price is pumping but 1 key risk remain

Humacyte (NASDAQ: HUMA) stock price has surged hard since I wrote about it in April. It soared to a high of $9.35 on Thursday and is now trading at its highest point since December 2021. It has risen for seven straight weeks and is up by almost 370% from its lowest swing this year. The […]

Interesting HUMA Put And Call Options For July 19th

Top Buys by Directors: Binder's $667.5K Bet on HUMA

Thursday 5/16 Insider Buying Report: HUMA

HUMA Stock Earnings: Humacyte Misses EPS for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Humacyte (NASDAQ:HUMA) just reported results for the first quarter of 2024.Huma...

HUMA Stock Earnings: Humacyte Misses EPS for Q1 2024

HUMA stock results show that Humacyte missed analyst estimates for earnings per share the first quarter of 2024.

Humacyte First Quarter 2024 Financial Results and Business Update

-Biologics License Application (BLA) for HAV™ Accepted by FDA- -BLA Granted Priority Review for Vascular Trauma Indication; PDUFA date set for August...

Here’s why the Humacyte (HUMA) stock price is pumping

Humacyte (NASDAQ: HUMA) stock price is pumping this week. It jumped by over 10% on Friday, continuing a spectacular rally that started last week. It has soared by 40% from its lowest point this month and is trading at its highest point since February 29th. The reason why the stock surged is because a senior […]

Commit To Buy Humacyte At $2.50, Earn 42.4% Annualized Using Options

Humacyte to Host Virtual KOL Event “Hemodialysis Access: A Crossroads of Care,” on March 28, 2024

DURHAM, N.C., March 26, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally...

HUMA Stock Earnings: Humacyte Meets EPS for Q4 2023

HUMA stock results show that Humacyte met analyst estimates for earnings per share the fourth quarter of 2023.

Humacyte Fourth Quarter and Year End 2023 Financial Results and Business Update

-Biologics License Application (BLA) for HAV™ Accepted by FDA on February 8, 2024- -BLA Granted Priority Review for Vascular Trauma Indication; PDUFA...

Humacyte to Present 2023 Fourth Quarter and Year-End Financial Results and Provide Corporate Update on March 22, 2024

DURHAM, N.C., March 18, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally...

Humacyte, Inc. to Present at the TD Cowen 44th Annual Health Care Conference

DURHAM, N.C., March 01, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

Pre-market stock movers are worth checking on Friday as investors prepare for the last day of trading this week with all of the latest news!